Published in Biotech Business Week, October 18th, 2004
This announcement follows a recent decision by the U.S. Food and Drug Administration (FDA) to grant Procter & Gamble fast track status for its formulation of Intrinsa, an investigational female testosterone patch, based upon data for its two phase III trials.
LibiGel utilizes Antares Pharma's propriety...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.